

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE	EFFECTIVE DATE	NU	MBER
February 24, 2022	December 1, 2020		08-20-66
SUBJECT			ВҮ
Clinic Payment for SAR	Ith Center and Rural Heal S-CoV-2 Vaccine	th	Sally h. Kozel
Administration			Sally A. Kozak,
			Deputy Secretary
			Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <u>https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx</u>.

PURPOSE:

The purpose of this bulletin is to inform Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) that the Department of Human Services (Department) is implementing an alternative payment methodology (APM): 1) to pay the Medical Assistance (MA) Program Fee Schedule rate for the administration of the novel coronavirus (SARS-CoV-2) vaccine during a SARS-CoV-2 vaccine-only visit for dates of service on and after December 1, 2020, and 2) pays the enhanced MA Program Fee Schedule rate for the administration of SARS-CoV-2 vaccine to homebound MA beneficiaries during a SARS-CoV-2 vaccine-only visit for dates of service on and after April 1, 2021.

SCOPE:

This bulletin applies to all FQHCs and RHCs enrolled in the MA Program that administer immunizations to MA beneficiaries. The APM is for providers that render services in the fee-for-service (FFS) delivery system. Providers rendering services to MA beneficiaries in the managed care delivery system must utilize the SARS-CoV-2 vaccine administration codes for Department tracking purposes but should contact the appropriate managed care organization (MCO) with any billing questions related to SARS-CoV-2 vaccine-only visits.

BACKGROUND:

To address the additional costs associated with administration of the SARS-CoV-2 and support the administration of the vaccines to MA beneficiaries in the FQHC and RHC settings, the Department submitted a Disaster Relief State Plan Amendment to request, in part, the

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

Fee-for-service provider service center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Con tact-Information-for-Providers.aspx. Centers for Medicare & Medicaid Services' (CMS) approval to pay FQHCs and RHCs for the administration of SARS-CoV-2 vaccines during a vaccine-only visit in which no other services are provided on the same date. The Department received CMS approval on October 14, 2021, effective with dates of service from December 1, 2020, through the end of the public health emergency.

In addition, although FQHCs and RHCs can currently render services to MA beneficiaries in their homes, the provision of SARS-CoV-2 vaccines to MA beneficiaries who are homebound presents unique challenges to provide the appropriate vaccine storage temperatures, handling, and administration to ensure safe and effective vaccination. The Department sought CMS approval to pay an enhanced fee for vaccine administration to beneficiaries who are homebound. MA beneficiaries who are homebound include, but are not limited to, those individuals that need help from another person or from medical equipment such as crutches, a walker, or a wheelchair to leave their home, those individuals whose medical provider believes that their health or illness could get worse if they leave their home, and it is difficult for them to leave their home and they typically cannot do so. See MA Bulletin 01-21-04, entitled "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound." The Department pays an enhanced fee to FQHCs and RHCs to administer SARS-CoV-2 vaccines to MA beneficiaries who are homebound when no other services that would constitute a billable encounter are provided to the MA beneficiary, effective with dates of service from April 1, 2021, through the end of the public health emergency.

The Department is implementing the APM to pay FQHCs and RHCs the MA Program Fee Schedule rate for the administration of SARS-CoV-2 vaccines when a beneficiary receives the immunization and no other services that would qualify the visit as an encounter are provided on the same day, effective for dates of service on and after December 1, 2020 and an enhanced fee for the administration of SARS-CoV-2 vaccines to MA beneficiaries who are homebound when no other services that would constitute a billable encounter effective with dates of service from April 1, 2021. The SARS-CoV-2 vaccines can be administered by any FQHC or RHC staff who is authorized by Pennsylvania's Department of Health to administer the vaccines.

The Department developed this APM to pay FQHCs and RHCs for the administration of SARS-CoV-2 vaccines based upon statutory requirement 42 U.S.C.A. § 1396a(bb)(6). The APM must be agreed to by each individual FQHC and RHC.

DISCUSSION:

Vaccine Administration CPT Codes

The FQHCs and RHCs must use the procedure codes on the MA Program Fee Schedule for the administration of the SARS-CoV-2 vaccine. The procedure codes are distinct to each SARS-CoV-2 vaccine and the specific dose in the required schedule. This level of specificity offers the ability to track each vaccine dose, even when the vaccine product is not reported, such as when the vaccine is available at no cost. These codes are to be used by providers to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered to MA beneficiaries.

The Department added the following CPT codes for the administration of the SARS-CoV-2 vaccines to the MA Program Fee Schedule:

- 0001A and 0002A for Pfizer, Inc., effective December 1, 2020;
- 0011A and 0012A for Moderna, Inc., effective December 1, 2020;
- 0031A for Janssen Biotech, Inc., effective February 27, 2021;
- 0003A for Pfizer, Inc., effective August 12, 2021; and,
- 00013A for Moderna, Inc., effective August 12, 2021.

CPT Codes for Administration of SARS-CoV-2 Vaccines to Homebound MA Beneficiaries

On July, 29, 2021, the Department issued MA Bulletin <u>01-21-04</u>, entitled "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound," to inform providers that the MA Program makes an enhanced payment for the administration of SARS-CoV-2 vaccines to MA beneficiaries who are homebound, effective for dates of service on and after April 1, 2021.

The Department pays FQHCs and RHCs the enhanced fee to administer SARS-CoV-2 vaccines to MA beneficiaries who are homebound when no other services that would constitute an FQHC or RHC encounter are provided. The enhanced fee is \$75.00 and was developed to account for the additional costs associated with traveling and administering SARS-CoV-2 vaccines to MA beneficiaries who are homebound. For the period of April 1, 2021, through June 7, 2021, the Department added the pricing modifier AT and place of service (POS) 12 (Home) to the SARS-CoV-2 administration codes to indicate the vaccine was administered to a beneficiary who is homebound. FQHCs and RHCs are to use the AT modifier and POS 12 with the applicable procedure code to receive the enhanced payment when billing for SARS-CoV-2 vaccines administered from to beneficiaries who are homebound during this timeframe.

On June 8, 2021, CMS announced the Medicare program would provide an additional payment of \$35.00 for SARS-CoV-2 vaccinations administered to individuals in their homes. This payment is made in addition to the current \$40.00 SARS-CoV-2 administration fee when the vaccine is administered to an individual in their home. To facilitate this additional payment, CMS established CPT code M0201 to utilize when SARS-CoV-2 vaccines are administered to individuals in their homes.

In response, the Department added CPT code M0201 to the MA Program Fee Schedule, effective for dates of service on and after June 8, 2021. Procedure code M0201 is to be billed with the applicable SARS-CoV-2 administration code by FQHCs and RHCs when billing for SARS-CoV-2 vaccines administered on or after June 8, 2021, to beneficiaries who are homebound. The FFS MA Program Fee Schedule rate for procedure code M0201 is \$35.00. The MA Program does not make an enhanced payment to providers when SARS-CoV-2 vaccines are administered to individuals who are in the home that are not homebound.

PROCEDURE:

Effective with dates of services on and after December 1, 2020, the Department utilizes an APM, for FQHCs and RHCs that agree to accept it, to pay the MA Program Fee Schedule rate for the administration of SARS-CoV-2 vaccines, when a beneficiary in the MA Program's FFS delivery system receives the immunization and no other services that would qualify the visit as an encounter are provided.

The APM is effective for dates of service on and after December 1, 2020. A request to opt-in to the APM as of December 1, 2020, must be submitted by the FQHC's or RHC's Chief Financial Officer via email to the Department at FinancialGatekeeper@pa.gov within 30 days of the issuance of this MA Bulletin and must include both the FQHC's or RHC's nine-digit provider identification number and four-digit service location number for which the opt-in is to be applied. The email should indicate that the FQHC or RHC is accepting the APM. Any FQHC or RHC that wishes to opt-in in the future must do so ten business days in advance of submitting a claim to the Department. An FQHC or RHC can opt-out of the APM, after initially opting in, by following these same directions. If the FQHC or RHC has previously opted out and chooses to opt-in, the Chief Financial Officer must send an opt-in request via email to the Department at FinancialGatekeeper@pa.gov, with the requested effective date for the opt-in. The Department will review and process the opt-in request and notify the FQHC or RHC of the effective date of the opt-in.

Claims for SARS-CoV-2 vaccine-only visits submitted within 60 days of the issuance of this bulletin will not be subject to the time frames for submission of claims in 55 Pa. Code § 1101.63(b).

FQHCs and RHCs are to bill with the applicable CPT codes below when the SARS-CoV-2 vaccine is administered to a MA beneficiary, including those administered to homebound beneficiaries, and no other services that constitute an encounter are rendered on that date. When the SARS-CoV-2 vaccine is administered during a billable encounter, FQHCs and RHCs are to bill procedure code T1015 to be paid their provider-specific Prospective Payment System rate and the appropriate SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine. FQHCs and RHCs may not bill the Department for administration of SARS-CoV-2 vaccines they receive at no cost or for the administration of the vaccine for which they will be paid by another entity to administer.

<u>Vaccine</u> Manufacturer	<u>Code</u>	Code Description	
--------------------------------	-------------	------------------	--

	0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
Pfizer, Inc.	0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
	0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose
	0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
Moderna, Inc.	0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
	0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose
Janssen Biotech, Inc.	0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose
N/A	M0201	COVID-19 vaccine administration inside a patient's home; reported only once per individual home, per date of service, when only COVID-19 vaccine administration is performed at the patient's home

The attachments to this MA Bulletin identify the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, MA fee, and limits for the procedure codes for providers submitting MA claims during the identified date range.

Providers may access the online version of the MA Program Fee Schedule at: <u>https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx</u>.

FQHCs and RHCs are to refer to the SARS-CoV-2 vaccine administration billing instructions in this MA Bulletin, MA Bulletin 01-21-04, and instructions in the <u>MA Program's</u> <u>Provider Handbook and Billing Guides</u>.

Additional information and guidance pertaining to the COVID-19 vaccines can be found at the following links:

- American Medical Association <u>https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance.</u>
- Centers for Disease Control and Prevention
 <u>https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.</u>
- Centers for Medicare & Medicaid Services
 <u>https://www.medicaid.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html.</u>
- PA Department of Health
 1-877-PA HEALTH (1-877-724-3258)
 https://www.health.pa.gov/Pages/default.aspx.

ATTACHMENTS:

Attachment A – Procedure Codes for the Administration of SARS-CoV-2 Vaccines by FQHCs and RHCs, Effective December 1, 2020, through March 14, 2021

Attachment B – Procedure Codes for the Administration of SARS-CoV-2 Vaccines by FQHCs and RHCs, Effective March 15, 2021, through March 31, 2021

Attachment C – Procedure Codes for the Administration of SARS-CoV-2 Vaccines by FQHCs and RHCs, Effective April 1, 2021, through June 7, 2021

Attachment D – Procedure Codes for the Administration of SARS-CoV-2 Vaccines by FQHCs and RHCs, Effective June 8, 2021, through August 11, 2021

Attachment E – Procedure Codes for the Administration of SARS-CoV-2 Vaccines by FQHCs and RHCs, Effective August 12, 2021

	Procedure Codes for the Adn Effective Dec					•	s and RH(Cs,	
Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
	Immunization administration by intramuscular	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	openanty						
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	080	50,99			\$16.94	No	per da
	Immunization administration by intramuscular							-	1
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	081	72,99			\$16.94	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	80	50,99			\$28.39	No	per da
	Immunization administration by intramuscular								-
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	081	72,99			\$28.39	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,					once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	50,99			\$16.94	No	per da

	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	72,99	\$16.94	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	080	50,99	\$28.39	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	72,99	\$28.39	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus						
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,			once
0031A	particles/0.5mL dosage, single dose	08	080	50,99	\$28.39	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus						
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,			once
0031A	particles/0.5mL dosage, single dose	08	081	72,99	\$28.39	No	per day

	Procedure Codes for the Adm Effective Ma						and RHC	S,	
Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Reguired	Limit
couc	Immunization administration by intramuscular	1960	opecially	Scivice	mounter	Wiodifiel	MATCC	nequireu	
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	080	50,99			\$40.00	No	per d
	Immunization administration by intramuscular			/			,		
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					onc
0001A	reconstituted; first dose	08	081	72,99			\$40.00	No	per d
	Immunization administration by intramuscular								Ľ.
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					onc
0002A	reconstituted; second dose	08	080	50,99			\$40.00	No	per d
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					onc
0002A	reconstituted; second dose	08	081	72,99			\$40.00	No	per d
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,					onc
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	50,99			\$40.00	No	per d

	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	72,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	080	50,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	72,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus						
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,			once
0031A	particles/0.5mL dosage, single dose	08	080	50,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus						
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,			once
0031A	particles/0.5mL dosage, single dose	08	081	72,99	\$40.00	No	per day

	Procedure Codes for the Adı Effective	ministrati e April 1,				•	s and RH(Cs,	
Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent								once
0001A	reconstituted; first dose	08	080	12	AT		\$75.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	080	50,99			\$40.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent								once
0001A	reconstituted; first dose	08	081	12	AT		\$75.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	081	72,99			\$40.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent								once
0002A	reconstituted; second dose	08	080	12	AT		\$75.00	No	per day

		1					7	
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,				once
0002A	reconstituted; second dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							
	preservative free, 30 mcg/0.3mL dosage, diluent							once
0002A	reconstituted; second dose	08	081	12	AT	\$75.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,				once
0002A	reconstituted; second dose	08	081	72,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	12	AT	\$75.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	12	AT	\$75.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	72,99		\$40.00	No	per day

1			1			1			-
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	08	080	12	AT		\$75.00	No	once per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,					once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	080	50,99			\$40.00	No	per day
				/			7.000		1
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	12	AT		\$75.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,					once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	72,99			\$40.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (coronavirus disease								
	[COVID-19]) vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free, 5x1010 viral								once
0031A	particles/0.5mL dosage, single dose	08	080	12	AT		\$75.00	No	per day
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (coronavirus disease								
	[COVID-19]) vaccine, DNA, spike protein, adenovirus								
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,					once
0031A	particles/0.5mL dosage, single dose	08	080	50,99			\$40.00	No	per day

	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (coronavirus disease							
	[COVID-19]) vaccine, DNA, spike protein, adenovirus							
	type 26 (Ad26) vector, preservative free, 5x1010 viral							once
0031A	particles/0.5mL dosage, single dose	08	081	12	AT	\$75.00	No	per day
	Immunization administration by intramuscular	-						
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (coronavirus disease							
	[COVID-19]) vaccine, DNA, spike protein, adenovirus							
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,				once
0031A	particles/0.5mL dosage, single dose	08	081	72,99		\$40.00	No	per day

	Procedure Codes for the Adm Effective Ju					•	and RHC	S,	
Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
	Immunization administration by intramuscular							•	
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	080	50,99			\$40.00	No	per da
	Immunization administration by intramuscular								-
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	081	72,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	080	50,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	081	72,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,					once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	50,99			\$40.00	No	per da

	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	72,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease						
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,			once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	080	50,99	\$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease			42.24.22			
00404	[COVID-19]) vaccine, mRNA-LNP, spike protein,		004	12,31,32,	<u> </u>		once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	72,99	 \$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus			12.24.22			
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,			once
0031A	particles/0.5mL dosage, single dose	08	080	50,99	 \$40.00	No	per day
	Immunization administration by intramuscular						
	injection of severe acute respiratory syndrome						
	coronavirus 2 (SARS-CoV-2) (coronavirus disease						
	[COVID-19]) vaccine, DNA, spike protein, adenovirus						
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,	4.0.00		once
0031A	particles/0.5mL dosage, single dose	08	081	72,99	\$40.00	No	per day
	COVID-19 vaccine administration inside a patient's						
	home; reported only once per individual home, per						
	date of service, when only COVID-19 vaccine			42	40- 00		once
M0201	administration is performed at the patient's home	08	080	12	\$35.00	No	per day
	COVID-19 vaccine administration inside a patient's						
	home; reported only once per individual home, per						
	date of service, when only COVID-19 vaccine				40		once
M0201	administration is performed at the patient's home	08	081	12	\$35.00	No	per day

		Effective	e August	12, 202	1				
Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	080	50,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0001A	reconstituted; first dose	08	081	72,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	080	50,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0002A	reconstituted; second dose	08	081	72,99			\$40.00	No	per da
	Immunization administration by intramuscular								
	injection of severe acute respiratory syndrome								
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease								
	[COVID-19]) vaccine, mRNA-LNP, spike protein,								
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,					once
0003A	reconstituted; third dose	08	080	50,99			\$40.00	No	per da

1	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,							
	preservative free, 30 mcg/0.3mL dosage, diluent			12,31,32,				once
0003A	reconstituted; third dose	08	081	72,99		\$40.00	No	per day
	Immunization administration by intramuscular			/		† . .		1 /
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular			,				, ,
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0011A	preservative free, 100 mcg/0.5mL dosage; first dose	08	081	72,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0012A	preservative free, 100 mcg/0.5mL dosage; second dose	08	081	72,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0013A	preservative free, 100 mcg/0.5mL dosage; third dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (Coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein,			12,31,32,				once
0013A	preservative free, 100 mcg/0.5mL dosage; third dose	08	081	72,99		\$40.00	No	per day

-				1	1	T		
	Immunization administration by intramuscular							
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (coronavirus disease							
	[COVID-19]) vaccine, DNA, spike protein, adenovirus							
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,				once
0031A	particles/0.5mL dosage, single dose	08	080	50,99		\$40.00	No	per day
	Immunization administration by intramuscular	-						
	injection of severe acute respiratory syndrome							
	coronavirus 2 (SARS-CoV-2) (coronavirus disease							
	[COVID-19]) vaccine, DNA, spike protein, adenovirus							
	type 26 (Ad26) vector, preservative free, 5x1010 viral			12,31,32,				once
0031A	particles/0.5mL dosage, single dose	08	081	72,99		\$40.00	No	per day
	COVID-19 vaccine administration inside a patient's							
	home; reported only once per individual home, per							
	date of service, when only COVID-19 vaccine							once
M0201	administration is performed at the patient's home	08	080	12		\$35.00	No	per day
	COVID-19 vaccine administration inside a patient's							
	home; reported only once per individual home, per							
	date of service, when only COVID-19 vaccine							once
M0201	administration is performed at the patient's home	08	081	12		\$35.00	No	per day